Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain

Translational Psychiatry

Volumn 7, Issue 1, 2017, Pages

  Purves Tyson, T D ^a,b,c   Owens, S J ^a,b,c   Rothmond, D A ^a,b   Halliday, G M ^b,c   Double, K L ^d   Stevens, J ^a,d   McCrossin, T ^d   Shannon Weickert, C ^a,b,c  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATIC CARBOXYLIC ACID; CARBOXYLYASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER; AMINE OXIDASE (FLAVIN CONTAINING); COMT PROTEIN, HUMAN; DRD3 PROTEIN, HUMAN; NEUROLEPTIC AGENT; SLC18A2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; DOPAMINE METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MESENCEPHALON; POLYMERASE CHAIN REACTION; PRESYNAPTIC NERVE; PROTEIN EXPRESSION; SCHIZOPHRENIA; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NEOSTRIATUM; NERVE ENDING; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUTOPSY; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; MONOAMINE OXIDASE; NEOSTRIATUM; POLYMERASE CHAIN REACTION; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; SCHIZOPHRENIA; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 85026416564     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.257     Document Type: Article

References (69)

1. Pycock CJ, Carter CJ, Kerwin RW. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 1980; 34: 91-99.
2. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull 2009; 35: 549-562.
3. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
4. Seeman P, Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-1219.
5. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5: 267-271.
6. Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014; 282C: 248-257.
7. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal 2013; 11: 34.
8. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-239.
9. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Arch Gen Psychiatry 2012; 69: 776-786.
10. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of (18)F/(11)C)-DOPA PET studies. Schizophr Bull 2013; 39: 33-42.
11. Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, et al. Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain 2013; 136(Pt 11): 3242-3251.
12. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67: 443-462.
13. Kapur S, Austin MC, Underwood MD, Arango V, Mann JJ. Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus. Brain Res Mol Brain Res 1993; 18: 121-126.
14. Vrana SL, Vrana KE, Koves TR, Smith JE, Dworkin SI. Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J Neurochem 1993; 61: 2262-2268.
15. Leviel V, Gobert A, Guibert B. The glutamate-mediated release of dopamine in the rat striatum: Further characterization of the dual excitatory-inhibitory function. Neuroscience 1990; 39: 305-312.
16. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Trans 1994; 8: 149-158.
17. Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC. Dopamine pathology in schizophrenia: Analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry 2012; 3: 31.
18. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 2004; 121: 60-69.
19. Rice MW, Roberts RC, Melendez-Ferro M, Perez-Costas E. Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 2016; 221: 185-201.
20. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: From structure to function. Physiol Rev 1998; 78: 189-225.
21. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-151.
22. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43.
23. Goldstein M, Harada K, Meller E, Schalling M, Hokfelt T. Dopamine autoreceptors. Biochemical, pharmacological, and morphological studies. Ann N Y Acad Sci 1990; 604: 169-175.
24. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203.
25. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 1998; 95: 7731-7736.
26. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, et al. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 2003; 100: 4305-4309.
27. Schmauss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 1993; 90: 8942-8946.
28. Elmhurst JL, Xie Z, O'Dowd BF, George SR. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: Evidence for heterooligomerization. Brain Res Mol Brain Res 2000; 80: 63-74.
29. Karpa KD, Lin R, Kabbani N, Levenson R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol Pharmacol 2000; 58: 677-683.
30. Schmauss C. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J Neurosci 1996; 16: 7902-7909.
31. Owen R, Owen F, Poulter M, Crow TJ. Dopamine D2 receptors in substantia nigra in schizophrenia. Brain Res 1984; 299: 152-154.
32. Henry JP, Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol 1989; 38: 2395-2404.
33. Piccini PP. Dopamine transporter: Basic aspects and neuroimaging. Mov Disord 2003; 18: S3-S8.
34. Chaudhry FA, Edwards RH, Fonnum F. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Ann Rev Pharmacol Toxicol 2008; 48: 277-301.
35. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM, et al. Catechol O-methyltransferase mRNA expression in human and rat brain: Evidence for a role in cortical neuronal function. Neuroscience 2003; 116: 127-137.
36. Boulton AA, Eisenhofer G. Catecholamine metabolism. From molecular understanding to clinical diagnosis and treatment. Overview. Adv pharmacol 1998; 42: 273-292.
37. Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA, et al. Distribution of monoamine oxidase proteins in human brain: Implications for brain imaging studies. J Cereb Blood Flow Metab 2013; 33: 863-871.
38. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T, et al. Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 2010; 44: 59-70.
39. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM, et al. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry 2006; 60: 650-658.
40. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898-911.
41. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667.
42. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255-262.
43. Yang Y, Fung SJ, Rothwell A, Tianmei S, Weickert CS. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol Psychiatry 2011; 69: 63-70.
44. Reyes S, Cottam V, Kirik D, Double KL, Halliday GM. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord 2013; 28: 1351-1359.
45. Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A, et al. Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. Mol Psychiatry 2014; 19: 1258-1266.
46. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 1-12.
47. Purves-Tyson TD, Handelsman DJ, Double KL, Owens SJ, Bustamante S, Weickert CS. Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci 2012; 13: 95.
48. Tank AW, Xu L, Chen X, Radcliffe P, Sterling CR. Post-transcriptional regulation of tyrosine hydroxylase expression in adrenal medulla and brain. Ann N Y Acad Sci 2008; 1148: 238-248.
49. Lenartowski R, Goc A. Epigenetic, transcriptional and posttranscriptional regulation of the tyrosine hydroxylase gene. Int J Dev Neurosci 2011; 29: 873-883.
50. Haycock JW. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J Biol Chem 1990; 265: 11682-11691.
51. Grima B, Lamouroux A, Boni C, Julien JF, Javoy-Agid F, Mallet J. A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. Nature 1987; 326: 707-711.
52. Kaneda N, Kobayashi K, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, et al. Isolation of a novel cDNA clone for human tyrosine hydroxylase: Alternative RNA splicing produces four kinds of mRNA from a single gene. Biochem Biophys Res Commun 1987; 146: 971-975.
53. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol Psychiatry 2013; 74: 106-112.
54. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003; 28: 787-794.
55. Buckland PR, O'Donovan MC, McGuffin P. Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 1992; 108: 98-102.
56. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-1210.
57. Dean B, Hussain T. Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. Schizophr Res 2001; 52: 107-114.
58. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988; 2: 546-557.
59. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, Part I: Meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull 2013; 39: 22-32.
60. Chen KC, Yang YK, Howes O, Lee IH, Landau S, Yeh TL, et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. Schizophr Bull 2013; 39: 378-386.
61. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 2001; 49: 110-116.
62. Liu Z, Huang L, Luo XJ, Wu L, Li M. MAOA variants and genetic susceptibility to major psychiatric disorders. Mol Neurobiol 2016; 53: 4319-4327.
63. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476.
64. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003; 23: 2008-2013.
65. Dempster EL, Mill J, Craig IW, Collier DA. The quantification of COMT mRNA in post mortem cerebellum tissue: Diagnosis, genotype, methylation and expression. BMC Med Gen 2006; 7: 10.
66. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen J, Hyde TM, et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 2003; 28: 1521-1530.
67. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. J Hum Genet 2004; 75: 807-821.
68. Lipska BK, Lerman DN, Khaing ZZ, Weickert CS, Weinberger DR. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: Effects of antipsychotic drugs. Eur J Neurosci 2003; 18: 391-402.
69. Cohen OS, Weickert TW, Hess JL, Paish LM, McCoy SY, Rothmond DA, et al. A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples. Mol Psychiatry 2016; 21: 975-982.